Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody blocking cetuximab and egfr binding, its kit and hybridoma cell

A technology of cetuximab and kits, applied in chemical instruments and methods, methods based on microorganisms, biochemical equipment and methods, etc., capable of solving problems such as acute allergic reactions and effects

Active Publication Date: 2017-06-16
DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a problem that cannot be ignored when using antibody drugs for treatment is the impact of antibody immunogenicity on treatment. These immunogenicities will not only cause acute allergic reactions in the body, but also have a competitive inhibitory effect on the drug itself.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody blocking cetuximab and egfr binding, its kit and hybridoma cell
  • Antibody blocking cetuximab and egfr binding, its kit and hybridoma cell
  • Antibody blocking cetuximab and egfr binding, its kit and hybridoma cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] In order to make the technical means, creative features, goals and effects achieved by the present invention easy to understand, the present invention will be further described below in conjunction with specific illustrations.

[0018] Specifically, four aspects are involved: first, the preparation process of monoclonal antibody 15-B2-4-1; second, the specificity of binding of monoclonal antibody 15-B2-4-1 to cetuximab; third, Neutralizing properties of mAb 15-B2-4-1; IV, Amino acid sequence of mAb 15-B2-4-1.

[0019] 1. Preparation of monoclonal antibody by hybridoma technology

[0020] The main steps include: animal immunization, cell fusion, screening of hybridoma cells, cloning of hybridoma cells, preparation of monoclonal antibodies, etc.

[0021] (1) Animal immunization: 6-week-old BALB / C female mice were used. The antigen was commercialized cetuximab Erbitux. Conventional immunization method, the immunization route is subcutaneous injection. Mix equal volumes...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antibody for blocking combination of cetuximab and EGFR, a kit and a hybridoma cell thereof. The antibody includes an amino acid sequence expressed by at least one of SEQ NO.:4, SEQ NO.:5 and SEQ NO.:6. The antibody can specifically combine cetuximab and achieve a function of blocking the combination of the cetuximab and the EGFR. The antibody can be used as a positive control for evaluating the immunogenicity of the cetuximab and used for monitoring the sensitivity and specificity of the method. The antibody can also be used for monitoring the sensitivity and specificity of a method for measuring the biological activity of the cetuximab. The invention further discloses a hybridoma cell secreting the antibody and a kit using the antibody. The invention further provides a method for evaluating the neutralization performance of the antibody.

Description

technical field [0001] The invention belongs to the technical field of preparing monoclonal antibodies by hybridomas, and relates to the preparation of monoclonal antibodies and the determination of the binding activity of the monoclonal antibodies. [0002] The present invention provides isolated anti-cetuximab antibodies that are also capable of blocking the binding of cetuximab to its receptor epidermal growth factor receptor (EGFR). It can play an important role in the clinical analysis of the immunogenicity of cetuximab, and can be used as a positive control to monitor and evaluate the sensitivity and specificity of the immunogenicity test. Background technique [0003] In recent years, antibody drugs have been widely used in the clinical treatment of tumors, transplant rejection, infectious diseases, autoimmune diseases and other diseases due to their advantages of safety, effectiveness and high specificity. However, a problem that cannot be ignored when using antibod...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/42C12N5/20G01N33/577C12R1/91
Inventor 李慧刘钰山刘聪徐建喇玉娟黄应峰张杰邹准
Owner DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com